Ernexa Therapeutics Inc. financial data

Symbol
ERNA, ERNAW on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 13 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 74% % 32%
Debt-to-equity 452% %
Return On Equity -1262% % -494%
Return On Assets -229% % -40%
Operating Margin -2693% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29,154,431 shares -44%
Common Stock, Shares, Outstanding 7,854,000 shares 129%
Entity Public Float $17,500,000 USD 97%
Common Stock, Value, Issued $39,000 USD 129%
Weighted Average Number of Shares Outstanding, Basic 6,307,000 shares 593%
Weighted Average Number of Shares Outstanding, Diluted 6,307,000 shares 593%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $582,000 USD
Cost of Revenue $96,000 USD
General and Administrative Expense $5,163,000 USD -61%
Operating Income (Loss) $9,319,000 USD 41%
Nonoperating Income (Expense) $4,810,000 USD 83%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $14,129,000 USD 68%
Income Tax Expense (Benefit) $45,000 USD -250%
Net Income (Loss) Attributable to Parent $14,084,000 USD 68%
Earnings Per Share, Basic -2.24 USD/shares 95%
Earnings Per Share, Diluted -2.24 USD/shares 95%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,315,000 USD 67%
Assets, Current $3,133,000 USD 33%
Property, Plant and Equipment, Net $94,000 USD 11%
Operating Lease, Right-of-Use Asset $453,000 USD -32%
Goodwill $2,044,000 USD 0%
Other Assets, Noncurrent $110,000 USD -6.8%
Assets $5,834,000 USD 11%
Accounts Payable, Current $1,125,000 USD -35%
Employee-related Liabilities, Current $12,000 USD 0%
Accrued Liabilities, Current $898,000 USD -11%
Contract with Customer, Liability, Current $5,335,000 USD
Liabilities, Current $3,113,000 USD 6%
Operating Lease, Liability, Noncurrent $277,000 USD -42%
Other Liabilities, Noncurrent $43,000 USD -61%
Liabilities $3,433,000 USD -3.8%
Retained Earnings (Accumulated Deficit) $245,636,000 USD -6.1%
Stockholders' Equity Attributable to Parent $2,401,000 USD 41%
Liabilities and Equity $5,834,000 USD 11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,065,000 USD 45%
Net Cash Provided by (Used in) Financing Activities $2,254,000 USD 63%
Common Stock, Shares Authorized 150,000,000 shares 50%
Common Stock, Shares, Issued 7,854,000 shares 129%
Common Stock, Par or Stated Value Per Share 0.005 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,884,000 USD 9%
Deferred Tax Assets, Valuation Allowance $26,145,000 USD 0.47%
Deferred Tax Assets, Gross $26,404,000 USD 0.22%
Operating Lease, Liability $490,000 USD -28%
Lessee, Operating Lease, Liability, to be Paid $549,000 USD -30%
Property, Plant and Equipment, Gross $291,000 USD 13%
Operating Lease, Liability, Current $213,000 USD 2.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two $200,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year One $254,000 USD -7.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1193 pure 17%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $59,000 USD -42%
Lessee, Operating Lease, Liability, to be Paid, Year Three $95,000 USD -42%
Preferred Stock, Shares Issued 156,000 shares 0%
Preferred Stock, Shares Authorized 1,000,000 shares 0%
Unrecognized Tax Benefits $393,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $82,000 USD -99%
Additional Paid in Capital $247,997,000 USD 6.3%
Preferred Stock, Shares Outstanding 156,000 shares 0%
Depreciation, Depletion and Amortization $18,000 USD -54%
Deferred Tax Assets, Net of Valuation Allowance $259,000 USD -20%
Share-based Payment Arrangement, Expense $1,496,000 USD -1.6%
Preferred Stock, Par or Stated Value Per Share 0.005 USD/shares 0%